FCMI
ALXO icon

Foresite Capital Management IV’s ALX Oncology ALXO Stock Holding History

Foresite Capital Management IV’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-785,945
Closed -$58M – 14
2021
Q1 		$58M Sell
785,945
-187,569
-19% -$14.8M 6.94% 6
2020
Q4 		$83.9M Hold
973,514
– – 9.12% 4
2020
Q3 		$36.7M Buy
+973,514
New +$38.3M 8.29% 5

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Foresite Capital Management IV's ALXO Position: Q2 2021 in Review

Foresite Capital Management IV sold out of ALX Oncology (ALXO) in Q2 2021, closing a stake of 785,945 shares — an estimated $58M sold.

Foresite Capital Management IV first reported a position in ALXO in Q3 2020 and held it in 3 quarters. The position peaked at $83.9M in Q4 2020. 104 funds tracked by Wall St. Rank hold ALXO as of Q2 2021.

  • Foresite Capital Management IV reported no remaining ALX Oncology position as of Q2 2021 after selling out during the quarter.
  • Foresite Capital Management IV sold 785,945 ALX Oncology shares in Q2 2021, an estimated $58M.
  • Foresite Capital Management IV first reported a position in ALX Oncology in Q3 2020 and held it in 3 quarters.
  • Foresite Capital Management IV's ALX Oncology position peaked at $83.9M in Q4 2020.
  • 104 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2021.

Based on Foresite Capital Management IV's 13F filing for Q2 2021, filed 16 Aug 2021.